In one approach, researchers coupled Vibrio cholerae sialidase with trastuzumab; the resulting conjugate, denoted T-Sia, demonstrated the ability to desialylate HER2+ BC cells in vitro, resulting in the removal of Siglec ligands and ultimately enhancing the efficacy of NK cells in killing cancer cells 55. Here, ERBB2 is linked to breast cancer.